Shenyang Xingqi Pharmaceutical Co., Ltd. (300573) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

With a growth in Net Profit of 40.39%, the company declared Very Positive results in Mar 25

OPERATING CASH FLOW(Y) Highest at CNY 524.17 MM
ROCE(HY) Highest at 25.82%
NET SALES(Q) At CNY 528.5 MM has Grown at 52.83%

With ROE of 28.64%, it has a very attractive valuation with a 7.09 Price to Book Value

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CNY 12,474 Million (Large Cap)

P/E

25.00

Industry P/E

Dividend Yield

2.40%

Debt Equity

-0.10

Return on Equity

28.64%

Price to Book

7.09

Revenue and Profits:

Net Sales:

618 Million

(Quarterly Results - Jun 2025)

Net Profit:

189 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-1.05%

6 Months

35.71%

1 Year

19.09%

2 Years

-12.13%

3 Years

72.36%

4 Years

56.16%

5 Years

67.18%

Shenyang Xingqi Pharmaceutical Co., Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

33.24%

EBIT Growth (5y)

63.33%

EBIT to Interest (avg)

91.89

Debt to EBITDA (avg)

Net Debt is too low

Net Debt to Equity (avg)

-0.18

Sales to Capital Employed (avg)

0.92

Tax Ratio

15.39%

Dividend Payout Ratio

55.32%

Pledged Shares

Institutional Holding

ROCE (avg)

25.75%

ROE (avg)

17.53%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

7.09

EV to EBIT

21.25

EV to EBITDA

17.95

EV to Capital Employed

7.80

EV to Sales

5.63

PEG Ratio

2.19

Dividend Yield

2.40%

ROCE (Latest)

36.69%

ROE (Latest)

28.64%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 15.71% vs 35.66% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 40.34% vs 96.78% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "618.00",
          "val2": "534.10",
          "chgp": "15.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "241.00",
          "val2": "179.00",
          "chgp": "34.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.30",
          "val2": "1.70",
          "chgp": "-23.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "188.90",
          "val2": "134.60",
          "chgp": "40.34%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "346.80%",
          "val2": "285.90%",
          "chgp": "6.09%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 32.17% vs 17.58% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 40.88% vs 13.37% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,918.00",
          "val2": "1,451.20",
          "chgp": "32.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "512.70",
          "val2": "349.40",
          "chgp": "46.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "6.50",
          "val2": "1.90",
          "chgp": "242.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "338.10",
          "val2": "240.00",
          "chgp": "40.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "212.30%",
          "val2": "178.00%",
          "chgp": "3.43%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

618.00

534.10

15.71%

Operating Profit (PBDIT) excl Other Income

241.00

179.00

34.64%

Interest

1.30

1.70

-23.53%

Exceptional Items

0.00

Consolidate Net Profit

188.90

134.60

40.34%

Operating Profit Margin (Excl OI)

346.80%

285.90%

6.09%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 15.71% vs 35.66% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 40.34% vs 96.78% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

1,918.00

1,451.20

32.17%

Operating Profit (PBDIT) excl Other Income

512.70

349.40

46.74%

Interest

6.50

1.90

242.11%

Exceptional Items

0.00

Consolidate Net Profit

338.10

240.00

40.88%

Operating Profit Margin (Excl OI)

212.30%

178.00%

3.43%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 32.17% vs 17.58% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 40.88% vs 13.37% in Dec 2023

All Annual Results

Company CV

About Shenyang Xingqi Pharmaceutical Co., Ltd.

Shenyang Xingqi Pharmaceutical Co., Ltd.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available